Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2.5B |
| 2 |
Apple
AAPL
|
+$1.68B |
| 3 |
Tesla
TSLA
|
+$951M |
| 4 |
Johnson & Johnson
JNJ
|
+$750M |
| 5 |
UnitedHealth
UNH
|
+$703M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTXS
Citrix Systems Inc
CTXS
|
+$913M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$257M |
| 3 |
NVIDIA
NVDA
|
+$225M |
| 4 |
Vertiv
VRT
|
+$164M |
| 5 |
JPMorgan Chase
JPM
|
+$161M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.48% |
| 2 | Healthcare | 7.36% |
| 3 | Financials | 6.5% |
| 4 | Consumer Discretionary | 5.35% |
| 5 | Industrials | 3.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Arcus Biosciences
RCUS
$3.64B
| $2.61M | ﹤0.01% |
126,038
-42,672
| -25% | -$1.17M |
|
2027
PUT
Chemours
CC
$2.37B
| $2.6M | ﹤0.01% |
+85,000
| New | +$2.55M |
|
2028
Guidewire Software
GWRE
$14.2B
| $2.6M | ﹤0.01% |
41,546
-41,190
| -50% | -$2.44M |
|
|
AVAC
2029
DELISTED
Avalon Acquisition Inc. Class A Common Stock
AVAC
| $2.6M | ﹤0.01% |
253,567
| – | – |
|
|
CDMO
2030
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $2.6M | ﹤0.01% |
188,741
+65,231
| +53% | +$999K |
|
|
AVID
2031
DELISTED
Avid Technology Inc
AVID
| $2.6M | ﹤0.01% |
97,685
-75,276
| -44% | -$1.98M |
|
2032
PUT
Banco Bradesco
BBD
$36.7B
| $2.59M | ﹤0.01% |
+900,000
| New | +$2.92M |
|
2033
CALL
Union Pacific
UNP
$174B
| $2.59M | ﹤0.01% |
+12,500
| New | +$2.56M |
|
2034
Curtiss-Wright
CW
$25.5B
| $2.59M | ﹤0.01% |
15,487
-12,730
| -45% | -$2.12M |
|
2035
CALL
XPeng
XPEV
$11.6B
| $2.59M | ﹤0.01% |
+260,100
| New | +$2.34M |
|
2036
IPG Photonics
IPGP
$3.84B
| $2.58M | ﹤0.01% |
27,282
+3,002
| +12% | +$269K |
|
|
IRBT
2037
DELISTED
iRobot
IRBT
| $2.58M | ﹤0.01% |
53,610
+4,844
| +10% | +$256K |
|
2038
Zentalis Pharmaceuticals
ZNTL
$300M
| $2.58M | ﹤0.01% |
127,874
+11,276
| +10% | +$243K |
|
2039
PUT
Atlassian
TEAM
$37.8B
| $2.57M | ﹤0.01% |
+20,000
| New | +$3.18M |
|
|
INBX
2040
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $2.56M | ﹤0.01% |
106,603
+19,525
| +22% | +$574K |
|
2041
ASE Group
ASX
$82.2B
| $2.56M | ﹤0.01% |
408,369
-653,017
| -62% | -$3.83M |
|
|
SKX
2042
DELISTED
Skechers
SKX
| $2.56M | ﹤0.01% |
60,971
-36,252
| -37% | -$1.39M |
|
|
SCMA
2043
DELISTED
Seaport Calibre Materials Acquisition Corp. Class A Common Stock
SCMA
| $2.56M | ﹤0.01% |
250,000
-232,724
| -48% | -$2.35M |
|
2044
Prosperity Bancshares
PB
$8.86B
| $2.56M | ﹤0.01% |
35,184
+7,700
| +28% | +$556K |
|
2045
CALL
Warner Bros
WBD
$67.1B
| $2.55M | ﹤0.01% |
+269,200
| New | +$3.04M |
|
2046
Inspire Medical Systems
INSP
$1.74B
| $2.55M | ﹤0.01% |
10,131
+8,896
| +720% | +$1.9M |
|
|
PPYAW
2047
DELISTED
Papaya Growth Opportunity Corp. I Warrant
PPYAW
| $2.55M | ﹤0.01% |
250,000
| – | – |
|
2048
GSK
GSK
$106B
| $2.55M | ﹤0.01% |
72,551
-237,807
| -77% | -$7.92M |
|
2049
Milestone Pharmaceuticals
MIST
$152M
| $2.54M | ﹤0.01% |
641,353
+100,771
| +19% | +$530K |
|
2050
Regal Rexnord
RRX
$11.9B
| $2.53M | ﹤0.01% |
21,118
+1,562
| +8% | +$205K |
|
Similar funds
Barclays's Q4 2022 Portfolio in Review
As of Q4 2022, Barclays held 5,646 positions worth $223B, up 144% from $91.6B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $128B of net new capital in Q4 2022, opening 797 new positions and adding to 2,634 existing holdings. Its largest new stake was Seadrill: 1,546,558 shares worth $50.5M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $257M trimmed.
- Barclays's largest Q4 2022 buy was Seadrill: 1,546,558 shares worth $50.5M.
- Barclays added most to Microsoft in Q4 2022, an estimated $2.5B increase.
- Barclays's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $257M.
- Barclays fully exited Citrix Systems Inc in Q4 2022, selling an estimated $913M.
- Barclays's ten largest holdings make up 41% of its $223B portfolio in Q4 2022.
- Barclays opened 797 new positions and closed 385 in Q4 2022.
- Barclays's portfolio value rose 144% quarter-over-quarter to $223B.
Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.